SCHEMBL6327880

SCHEMBL6327880

Cc1cc(C(=O)N(C)C)cc(C)c1N1CC(Cc2ccc(F)cc2F)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.39
HTR7 P34969 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTGER1 P34995 2/20 0.35
CCR3 P51677 1/20 0.34
P2RX7 Q99572 2/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
FFAR1 O14842 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403964 0.89 PTGER1 (0.39) HTR7PTGDR2ALDH1A1TDP1PTGER1
SCHEMBL6329553 0.87 MAPK14 (0.39) MAPK14HTR7ALDH1A1TDP1CCR3
SCHEMBL6328913 0.86 MAPK14 (0.40) MAPK14HTR7ALDH1A1TDP1PTGER1
SCHEMBL6329273 0.85 HTR7 (0.44) MAPK14HTR7ALDH1A1
SCHEMBL6330806 0.85 P2RX7 (0.36) ALDH1A1TDP1CCR3P2RX7
SCHEMBL6326157 0.84 P2RX7 (0.36) MAPK14ALDH1A1TDP1PTGER1P2RX7
SCHEMBL6330114 0.84 P2RX7 (0.43) MAPK14HTR7ALDH1A1TDP1CCR3
SCHEMBL6327543 0.83 HTR7 (0.46) MAPK14HTR7ALDH1A1CCR3
SCHEMBL6335170 0.83 ATM (0.40) ALDH1A1MEN1KMT2A
SCHEMBL6336668 0.83 MEN1 (0.39) MAPK14ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US claimed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP claimed
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US disclosed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient MAPKAP1, MAPK1, MAPK8 MAPK14 64/4885HTR7 3340/4885PTGDR2 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.